ERBB2 and breast neoplasm: Our studies demonstrate that HER2-CAR-NK cells significantly inhibit JIMT-1 cell xenografts, and sPD-1 engineered into HER2-specific CAR further enhanced the inhibitory effect against trastuzumab-resistant breast tumors.